The aim of this study was to examine the relationship between family history of alcohol use disorder and striatal dopamine using positron emission tomography imaging. Participants were 84 healthy, 18-to 30-year-old, social drinkers recruited via fliers and newspaper advertisements. At assessment, participants completed measures of lifetime personal and family substance use and psychiatric symptoms. Participants underwent two consecutive positron emission tomography scans using the D 2 /D 3 dopamine receptor radioligand [ 11 C]raclopride BP ND was generally higher in FHP compared with FHN subjects across striatal subdivisions. There were no differences in ΔBP ND across regions. Negative subjective drug effects were more pronounced in FHP than in FHN subjects. While FHN subjects evidenced the expected positive relationship between ΔBP ND and positive subjective drug effects, this relationship was disrupted in FHP subjects. There are key differences in dopamine status and subjective stimulant drug experiences as a function of family AUD history. These findings have important implications for understanding risk for AUD development in FHP offspring.
INTRODUCTION
Alcohol use disorders (AUD) are common and contribute substantially to global disease burden (Hasin et al. 2007; Rehm et al. 2009) . A family history of alcoholism is associated with increased likelihood of AUD development in offspring, with genetic factors conferring 50-60 percent of risk (McGue 1999; Schuckit 2009 ). Yet, exact mechanisms underlying this increased risk are complex, multi-factorial and largely undetermined.
Preclinical and human studies have demonstrated that psychoactive substances, including alcohol, stimulants and opioids, increase dopamine concentrations in the striatum (Chiara & Imperato 1988; Leshner & Koob 1999; Boileau et al. 2003; Martinez et al. 2003; Volkow et al. 2004; Pierce & Kumaresan 2006; Constantinescu et al. 2008; Spreckelmeyer et al. 2011) , a key factor in rewarding effects of abused substances. Moreover, the dorsal striatum provides circuitry that consolidates habit-based learning, a form of cognition often more pronounced in persons with substance use disorders (Smith & Graybiel 2014) . In healthy young adults, baseline dopamine (DA) D 2 receptor availability in the nucleus accumbens was positively correlated with subjective scores of intoxication following alcohol administration (Yoder et al. 2005) . In alcohol-dependent persons compared with healthy controls, multiple studies have demonstrated lower levels of DA receptor availability and DA release (Hietala et al. 1994; Volkow et al. 1996; Heinz et al. 2004; Martinez et al. 2005) , changes that persist following detoxification (Volkow et al. 2002b; Volkow et al. 2007 ).
These differences in baseline DA receptor availability and release may predate development of alcohol misuse and contribute to risk for AUD development. Genetic studies have identified associations between DA receptor D 2 gene polymorphisms and alcohol dependence. The Taq1A polymorphism is among the most widely studied. While there is inconsistency in individual studies, metaanalyses have confirmed a modest increased risk of alcohol dependence (odds ratio (OR) 1.20-1.38) associated with the A1 allele (Munafo et al. 2007; Smith et al. 2008; Le Foll et al. 2009 ).
Yet, findings on the relationship between family history of alcoholism and DA D 2 receptor levels are inconsistent. Using positron emission tomography (PET) imaging with [ 11 C]raclopride, Volkow et al. (2006) found higher levels of baseline DA D 2 receptors in caudate and ventral striatum of non-alcoholic participants with a high density of alcoholism in their families (i.e., father and at least two second-degree relatives) compared with subjects with no first-degree or second-degree alcoholic relatives. In contrast, using similar PET procedures, Munro et al. (2006a) found no association between family history and baseline DA D 2 binding potential (BP ND ) or amphetamine-induced change in DA receptor BP ND (ΔBP ND ) on PET imaging; however, family history status was more variable in this study. Recently, using PET imaging with [
11 C]raclopride, Casey et al. reported decreased amphetamine-induced ΔBP ND in multi-generational family history positive (FHP) young adults with extensive personal histories of alcohol and drug use compared with both drugnaïve and drug-exposed family history negative (FHN) controls (2014) .
This study used [ 11 C]raclopride to explore the relationship between family history of AUD and striatal DA at baseline and following amphetamine administration in FHP compared with FHN young adults, with very limited alcohol and drug exposure. Our sample includes participants from the 2006 Munro study, but the current sample more than doubles the original report. This expanded sample allows us to refine the definition of FHP and provides increased power to detect differences as well as the opportunity to explore potential associations between striatal DA and subjective responses to amphetamine.
MATERIALS AND METHODS

Participants
Participants were 84 healthy young adults, ages 18-30 years, recruited via fliers and newspaper advertisements in the Baltimore area. Study exclusion criteria included the following: a current Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition axis I disorder (American Psychiatric Association 2000); drinking greater than 30 standard alcohol drinks per month; past 30-day illicit drug use; positive urine drug screen or alcohol breathalyzer at time of initial assessment or day of study procedures; reported maternal alcoholism; a medical condition prohibiting completion of study procedures; use of any medications in the past 30 days; or past 6-month treatment with antidepressant, appetite suppressant, DA, glucocorticoid, estrogen, neuroleptic, opiate or sedative hypnotic medications. Additionally, women who were pregnant, lactating or using hormonal birth control or hormone replacement medications were excluded. The study was approved by the Johns Hopkins University Institutional Review Board; all participants provided written informed consent.
Assessments
Participants were screened by telephone for preliminary study inclusion criteria and subsequently scheduled for an in-person assessment, including medical history, physical examination and collection of standard laboratory and diagnostic studies. Master's-level interviewers administered The Semi-Structured Assessment for the Genetics of Alcoholism (Bucholz et al. 1994 ) to determine the absence or presence of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition axis I disorders in the proband. Participants also completed the Perceived Stress Scale (Cohen et al. 1983) as part of the assessment battery.
Family history of AUD in first-degree and seconddegree relatives was first assessed using the Family Tree Questionnaire (Mann et al. 1985) . For all first-degree or second-degree relatives who scored 3 (suspected) or 4 (definite) on the Family Tree Questionnaire, the proband provided additional information on specific alcoholrelated problems using the Family History Assessment Module for alcohol (Rice et al. 1995) . Family History Assessment Module responses were used to classify relatives for alcohol abuse and/or dependence.
Participants were classified as FHP (N = 24) if they reported an AUD history (abuse and/or dependence) in at least one first-degree relative (father or sibling). Of these, 21 (87.5 percent) had a father with an AUD, with a mean number of affected first-degree relatives of 1.3 [standard deviation (SD) 1.27]. Although they did not contribute to the classification of FHP, we also examined the number of affected second-degree relatives (grandparents, aunts and uncles). Among the 24 participants, there was a total of 45 second-degree relatives with an AUD, with a mean of 1.9 (SD 1.45). Overall, the mean number of first-degree and second-degree relatives with an AUD in the FHP group was 3.1 (SD 1.39).
All other participants were classified as FHN (N = 60); thus, FHN participants could report an AUD in a secondsdegree relative. We also conducted sensitivity analyses examining only those FHN subjects with no first-degree or second-degree affected family members (N = 30).
Procedures
MRI magnetic resonance image assessment and mask fitting, PET scanning procedures, data acquisition and volumes of interest Detailed magnetic resonance image (MRI) assessment and mask fitting, PET scanning and data acquisition procedures have been described previously (Oswald et al. 2005; Munro et al. 2006a) and are provided in the Supporting Information. Briefly, MRI images were obtained using a spoiled gradient sequence for anatomical identification of brain structures. Participants were instructed not to ingest alcohol, drugs or over-thecounter medications for 48 hours prior to admission and were admitted the day before PET procedures. After a calorie-controlled, caffeine-free breakfast, PET images were acquired on the 3D GE Advance whole-body PET scanner (GE Medical Systems, Waukesha, WI, USA). After a 10-minute attenuation scan employing a rotating germanium-68 source, participants underwent two consecutive 90-minute PET scans with [ 11 C]raclopride, a benzamide antagonist at the DA D 2 and D 3 receptors, which has previously been shown to be sensitive to stimulant-induced changes in brain DA concentration (Volkow et al. 1994; Endres et al. 1997; Laruelle 2000) . The first scan was preceded at À5 minutes by an intravenous saline injection; the second scan was preceded at À5 minutes by 0.3 mg/kg amphetamine delivered over 3 minutes. The scanning image protocol consisted of up to 30 scan acquisitions in three-dimensional mode, starting from a 15-second duration and increasing to 5 minutes in length over the 90-minute period. Participants were under continuous cardiovascular monitoring during scans.
Each PET frame was reconstructed to 35 transaxial images of 128 × 128 matrices by a back-projection algorithm using the manufacturer-provided software and correcting for attenuation, scatter and dead time. PET frames were coregistered to the frame taken at 20 minutes by means of the mutual information theory as implemented in SPM2 (Maes et al. 1997; Friston & Penny 2003) to reduce head motions between frames.
For statistical analyses, we defined six volumes of interest (VOIs): anterior and posterior putamen (aPU and pPU), anterior and posterior caudate nucleus (aCN and pCN), and right and left ventral striatum (RtvS and LtvS). Based on prior research showing left and right striatal asymmetry (Larisch et al. 1998) , separate analyses were conducted for the right and left hemispheres of the ventral striatum. BP ND and change in BP ND (ΔBP ND ) were measured in each VOI.
Modeling of PET outcome measures
Binding potential (Innis et al. 2007 ) was estimated via the simplified reference tissue model with two parameters (SRTM2) (Lammertsma & Hume 1996; Wu & Carson 2002) and the multi-linear reference tissue method (MRTM2) (Ichise et al. 2003) using cerebellum as the reference tissue (Lammertsma & Hume 1996) . Specific binding of [ 11 C]raclopride is thought to be negligible in the cerebellum because the cerebellum is nearly devoid of DA D 2 /D 3 receptors . The VOIs defined on MRI were transferred to PET images to obtain time-activity curves of regions. ΔBP ND was estimated as the percent change in BP from the placebo scan to the amphetamine scan ([(BP placebo À BP amphetamine )/BP placebo ] × 100), with lower BP values during the amphetamine scan indicating greater levels of endogenous DA. Although release of endogenous DA is thought to be the biggest factor contributing to amphetamine-induced changes in [ 11 C]raclopride BP, 'DA release', the term typically used in the PET literature, probably results from several different mechanisms, which also include DA reuptake blockade, reverse transport of DA through the DA transporter (Schmitz et al. 2001 ) and possible actions on endogenous opioid systems (Schad et al. 2002) . Therefore, we use the term ΔBP ND .
Drug assays and subjective drug effects
In a subset of participants, blood was collected for amphetamine measurement at 15, 25, 55, 85 and 90 minutes following amphetamine injection. Plasma amphetamine levels were assessed by gas chromatography-mass spectroscopy (Quest Diagnostics, Lyndhurst, NJ, USA).
On a 5-point visual analog scale (0 = least and 4 = most), participants verbally rated the extent to which they were experiencing each of 10 stimulant drug effects. Visual analog scale ratings were collected 5 minutes before and 3, 6, 10, 15, 25, 55 and 85 minutes during the placebo and amphetamine PET scans. First, each participant's peak value across time points was identified for each item. Then a factor analysis on peak scores was performed to reduce the dimension of the data and to uncover underlying causes or factors. Using the iterated principal factor method, the analysis based on nine items yielded a positive (high, rush, good effect, liking, desire for drug) and negative factor (anxious, dizziness, dry mouth, distrust); the item fidgety did not clearly load on either factor and was excluded. Factor scores are a latent continuum ranging from approximately À3 to +3. In our sample, the calculated factor scores ranged from À2.1 to 2.8.
Statistical analyses
Demographic and baseline characteristics of FHP and FHN subjects were compared using χ 2 or Fisher's exact tests for categorical variables and t-tests or a nonparametric equivalent method for continuous variables. For the six selected VOIs, separate analysis of covariance models were constructed to examine the relationship between AUD family history and placebo BP ND and ΔBP ND .
We have previously reported significant sex effects on ΔBP ND (Munro et al. 2006b ) and so included sex as a covariate in analyses. Past 90-day binge drinking status (binge versus no binge; binge defined as >3 standard drinks for female and >4 standard drinks for male subjects) also was added to the model as a covariate as there was a trend of a higher likelihood of baseline binge drinking in FHP versus FHN subjects. Adaptive Holm procedure (Q) was used to correct p-values for multiple comparisons over the six VOIs (Hochberg & Benjamini 1990) . Finally, we conducted sensitivity analyses and repeated the models using a more stringent definition of FHN in which no first-degree or second-degree relative was classified with AUD (N = 30). We also examined subjective drug effects as a function of family history status. We compared positive and negative factor scores for FHN and FHP participants using analysis of covariance models. Again sex and baseline binge status were added to the models as covariates, and the adaptive Holm procedure was used for multiple comparison correction.
Finally, we examined the relationship between ΔBP ND and subjective factor scores as a function of family history status, adjusting for sex and baseline binge drinking status. All analyses were performed using SAS 9.3 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Baseline characteristics
Overall, participants were in their early twenties (mean age 22.8 years, SD 3.14), predominantly White (69.0 percent), majority men (60.7 percent) and had greater than a high school education (mean years 14.8, SD 1.78) ( Table 1 ). There were no demographic differences between FHP and FHN participants. More than half of participants (58.3 percent) reported at least one episode of binge drinking in the previous 90 days. Threequarters (75.0 percent) of the FHP participants reported at least one binge drinking episode during the past 90 days compared with 51.7 percent of FHN subjects; however, this difference just failed to achieve statistical significance (p = 0.050). Seven of 84 participants (8.3 percent) reported smoking more than 100 cigarettes in their lifetime, of which five were FHN and two were FHP. The mean duration of smoking for these seven participants was 22.7 months. Four of the seven (4.8 percent of the total sample) were current smokers, three FHN and 1 FHP. There were no family history differences in mean lifetime or current measures of smoking exposure. With respect to drug use, FHP were more likely than FHN participants to report ever using marijuana (78.3 versus 43.1 percent, p = 0.004). There was no family history difference in the number of subjects who reported >21 episodes of marijuana use in the past year; mean use were 2.16 times for FHN and 0.57 for FHP subjects. There were no other differences in lifetime or past-year drug use between FHP and FHN participants.
Dopamine binding potential (BP ND )
After confirming that SRTM2 and MRTM2 yielded essentially identical BP ND values (SRTM2 = 1.0,•MRTM2 = 0.009; R 2 > 0.999; using data from all scans), BP ND values given by MRTM2 were used in further analyses. In general, FHP participants had a higher mean BP ND than FHN participants across VOIs ( Using the more stringent definition of FHN in which no first-degree or second-degree family member was classified with AUD, results were similar. FHP participants had higher BP ND across brain regions compared with FHN subjects. Differences were significant in the aPU Stratified analyses by gender (not shown) for both the main and sensitivity analyses suggest that the significant findings were attributable to baseline differences in men rather than women.
Change in dopamine binding potential (ΔBP ND )
Area under the amphetamine plasma curves were analyzed in a subset of participants, and no difference was observed as a function of family history (FHP Area under the Curve (AUC) M = 2424, SD = 292; FHN Area under the Curve (AUC) M = 2327, SD = 729; p = 0.639). There were no significant family history differences for ΔBP ND in any of the six striatal brain regions regardless of which definition of FHN was used for analyses (Table 2 , lower section). Similar effects were obtained using the more stringent definition of FHN. No differences in positive drug effects were observed as a function of AUD family history. Similar to what we found with BP ND , stratified analyses by gender (not shown) suggest that these differences in subjective effects are primarily explained by differences in men as opposed to women.
Subjective effects of amphetamine
Correlation of subjective effects and BP ND and ΔBP ND Figure 1 shows the relationship between positive drug effects factor scores and ΔBP ND in FHP (left panels) and FHN subjects (right panels; defined as no first-degree or second-degree affected relatives). There was a significant positive relationship between positive subjective factor Table 4 shows the correlation results adjusted for sex and binge drinking. For the FHN subjects, positive drug ratings and ΔBP ND were significantly correlated in both regions in the adjusted analyses. There continued to be no evidence of relationship in FHP subjects after adjustment. Neither positive nor negative subjective factor ratings were related to baseline BP ND in FHP and FHN subjects. Analyses stratified by gender (not shown) revealed that men were responsible for this relationship between positive drug effects and ΔBP ND . There were no significant relationships between positive drug effects and ΔBP ND in women.
DISCUSSION
Prior brain imaging research on the relationship between AUD family history and striatal DA BP ND has been equivocal, probably resulting from differences across studies in definitions of family history status, prior alcohol and drug exposure in the probands, inclusion of sex as a covariate in analyses and typically small sample sizes (Wiesbeck et al. 1995) . The present study represents the largest sample studied to date using PET imaging to examine baseline DA BP ND , amphetamine-induced change in DA BP ND (ΔBP ND ), and positive and negative subjective drug effects simultaneously, as a function of family history of alcoholism. Similar to Volkow et al. (2006) , we found that social drinkers with a positive family history of alcoholism but no personal history of excessive drinking or alcohol or drug-related problems had significantly higher baseline [ 11 C]raclopride BP ND , consistent with higher DA D 2 /D 3 receptor availability, compared with FHN social drinkers. Specifically, we noted significant differences in the right ventral striatum, a region associated with reward, drive and motivation, and in the posterior caudate and anterior putamen, striatal regions associated with cognition. As suggested by Volkow, higher DA D 2 /D 3 receptors in our sample with increased genetic and/or epigenetic risk for development of AUD but without evidence of current alcohol problems may be protective against AUD. This explanation is supported by preclinical studies demonstrating lower striatal DA D 2 levels in selectively bred alcohol-preferring rats compared with non-alcoholpreferring rats (Stefanini et al. 1992; McBride et al. 1993) , increased administration of alcohol in alcoholpreferring rats in the presence of a DA D 2 receptor antagonist (Levy et al. 1991) and substantial reductions in alcohol intake of alcohol-preferring rats after artificially increasing DA D 2 receptor levels using an adenoviral vector (Thanos et al. 2001) . These findings highlight the potentially critical role of baseline DA D 2 receptor availability as a contributor to alcoholism risk and are consistent with this 'protection' hypothesis.
We found significant differences in DA D 2 /D 3 receptor availability in the right ventral striatum but not the left. This asymmetry is consistent with previous research demonstrating a preponderance of DA D 2 receptors in the right compared with the left striatum (Larisch et al. 1998) . Prior research suggests that right-sided neural pathways play a critical role in decision-making (Bechara 2005; Mohr et al. 2010 ). Right but not left ventral striatum ΔBP ND has been associated with unpredictable monetary rewards in healthy controls (Martin-Soelch et al. 2011), gambling in both healthy controls and pathological gamblers (Joutsa et al. 2012 ) and gambling severity in pathological gamblers (Joutsa et al. 2012) . Recent brain imaging research has shown a relationship between high impulsivity, a personality factor with a well-established association with substance use disorders, and blunted right ventral striatum activity (Oswald et al. 2007; Beck et al. 2009 ). Of particular relevance to the current study, Casey et al. (2014) reported blunted amphetamine-induced ΔBP ND in very high-risk young adults with multi-generational FH of substance use disorders and personal current regular alcohol and drug use Setiawan et al. (2014) observed increased ΔBP ND in FHP participants when alcohol was used to stimulate the dopaminergic system. In the present study, FHP and FHN subjects did not differ in magnitude of amphetamine-induced ΔBP ND , yet we observed significant differences between FHP and FHN participants in patterns of subjective drug effect ratings following amphetamine administration. Specifically, FHP subjects rated negative drug effects significantly higher than FHN subjects, and there was a tendency for FHP subjects to rate positive drug effects lower than FHN subjects although this observation did not reach statistical significance. It is possible that observed differences in baseline DA D 2 /D 3 receptor availability account for these findings. Previous studies have shown that DA D 2 /D 3 receptor availability is inversely related to subjective liking of methylphenidate (Volkow et al. 2002a) . Importantly, only FHN participants demonstrated the expected positive relationship between positive subjective drug effects and magnitude of amphetamine-induced ΔBP ND (Drevets et al. 2001; Oswald et al. 2005) . Indeed, this relationship was completely disrupted in FHP probands. Taken together, it appears that higher DA D 2 receptor levels are associated with greater negative drug effects and a disruption of the positive relationship between ΔBP ND magnitude and subjective drug reward.
An alternative explanation for the elevated baseline [ 11 C]raclopride BP ND is that it results from low tonic levels of endogenous synaptic DA in FHP participants. This DA deficiency model (Blum et al. 2000; Bowirrat & OscarBerman 2005) hypothesizes that increased AUD risk results from the reduced ability of FHP persons to generate DA, which results in reduced drug responsiveness. This would theoretically lead to increased consumption of alcohol/drugs to achieve comparable pleasurable effects as FHN persons. Unfortunately, findings derived from high-specific activity raclopride scans cannot differentiate whether high BP ND is a reflection of a low DA state versus high D 2 /D 3 receptor expression level. Future studies in FHP and FHN subjects could employ high-specific and low-specific activity raclopride scans, which would provide a comparison of B max between the two groups.
Our study employed amphetamine to interrogate the DA system rather than alcohol, highlighting the breadth of drug use risk conferred by a positive family history of alcoholism. An earlier study by our group observed differences in self-reported rates of alcohol, marijuana, sedative and cocaine use in high-density FHP compared with FHN subjects surveyed on local college campuses (McCaul et al. 1990) . Interestingly, FHP respondents also reported a younger age at first marijuana use, experience with less commonly used drugs and more personal drugrelated problems. In our current study, FHP subjects were more likely to report experimenting with marijuana despite careful screening for drug use. There is strong evidence that genetic risk for substance use disorders is largely non-specific and impacts across a wide range of drug classes (Kendler et al. 2003; Ystrom et al. 2014) . Thus, our observation of low DA D 2 in high-risk individuals may underpin risk across many different drug classes.
In addition to our large sample size, the current study has several important strengths. Our definition of FHP is consistent with Diagnostic Statistical Manual-5 (American Psychiatric Association 2013), in that relatives were considered AUD positive if they met either alcohol abuse or dependence criteria. FHP subjects averaged over three AUD family members and therefore would be considered high density and highest risk. Also notably, our large sample size enabled examination of more and less stringent definitions of FHN. In the FHN sample (N = 60) used in our primary analyses, half of our FHN subjects reported at least one second-degree AUD-affected relative. It is striking that there were very few changes in overall findings when we conducted sensitivity analyses using the more stringent definition of FHN that ruled out both first-degree and second-degree relatives. Future investigations should consider adoption of the more inclusive diagnostic system and family history classifications. This is the first PET study of family history effects that has had a sufficient number of female subjects to allow stratified analyses by sex. Importantly, we observed FH differences in baseline BP ND as well as amphetamineinduced subjective effects exclusively in male and not female subjects. These findings are in line with our own and others' reports of sex differences in striatal DA function (Munro et al. 2006b; Riccardi et al. 2011) as well as sex differences in response to stimulant administration in FHP and FHN participants (Gabbay 2005 ). There also is evidence of menstrual cycle effects on stimulant subjective drug effects (Evans et al. 2002; White et al. 2002) , highlighting the importance of investigating menstrual cycle phase in future family history studies.
Despite study strengths, our findings should be interpreted in the context of several limitations. First, data related to family member's history of alcohol use were collected from the probands and were not corroborated via interviews with additional family members. However, this likely resulted in an underestimation of FHP participants, decreasing the likelihood of observing group differences. Additionally, while there were no differences in mean drinking frequency or intensity, FHP subjects tended to be more likely to report past 90-day binge drinking compared with FHN participants, despite our rigorous efforts to recruit FHP and FHN subjects with comparable demographic, alcohol and drug use, and psychological profiles. It is important to note that, although binge drinking rates were different as a function of FH status, rates were low and in line with those reported for young adults in this age range (Naimi et al. 2003) .
The current findings provide important new insights into neural mechanisms of protective versus risk factors for substance use development. Our participants reported high-density AUD family histories but had no evidence of alcohol-related problems themselves. Although we cannot rule out development of problems in the future, our recruitment strategy may have resulted in highly resilient FHP participants, in whom high baseline DA D 2 /D 3 receptor levels are associated with more negative drug effects and a disruption of the expected relationship between DA release and positive subjective drug effects. In contrast, much of the research on AUD risk factors, including FH, personal alcohol/drug use, impulsivity and age of onset, has found similar baseline DA D 2 /D 3 receptor levels but blunted ΔBP ND in at-risk subjects. Our results highlight the importance of studying persons across a range of current drinking patterns and problems to ensure a more complete understanding of the different mechanisms that may be involved in conferring risk and resilience.
